Research at Idorsia Pharmaceuticals Ltd. has led to the discovery of aryl- and heteroaryl-sulfonamide derivatives acting as C-C chemokine receptor type 8 (CCR8) antagonists.
A Leo Pharma A/S patent describes new interleukin-17 (IL-17) modulators reported to be useful for the treatment of psoriasis, psoriatic arthritis, and radiographic axial spondyloarthritis (ankylosing spondylitis), among other diseases.
The Centre National de la Recherche Scientifique (CNRS) and the University of Strasbourg have patented nonpeptidergic oxytocin receptor agonists potentially useful for the treatment of aging, alcoholism, pain and more.
Fibrobiologics Inc. has announced the development of a novel artificial thymus organoid that can restore immune function in a severe combined immunodeficiency (SCID) mouse model.
CAR T-cell therapy that targets BCMA is an effective option for treating relapsed/refractory multiple myeloma, but there is a lack of persistence due to the inability to develop a memory phenotype.
CSPC Pharmaceutical Group Ltd. has obtained clearance from China’s National Medical Products Administration (NMPA) to conduct clinical trials in China with the first mRNA-lipid nanoparticles (LNP)-based CAR T-cell injection, SYS-6020.
The generation of anti-citrullinated protein autoantibodies (ACPA) are known key drivers in the pathogenesis of rheumatoid arthritis (RA) and are generated by peptidyl arginine deiminases (PADs).
Nervgen Pharma Corp. has outlined its plans to develop its new drug candidate, NVG-300, with a focus on three initial indications: ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).
Defence Therapeutics Inc. has demonstrated that its second-generation ARM-X anticancer vaccine is therapeutically effective against pre-established ovarian cancer (ID8 model) when combined with an anti-PD-1 immune checkpoint inhibitor.
RSS
